Cargando…

The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score

SIMPLE SUMMARY: The revised international prognostic scoring system (IPSS-R) represents the standard tool for prognostication in myelodysplastic syndromes (MDSs). It considers the degree of cytopenias together with the bone marrow blast count and the results of metaphase cytogenetics. Monocytes are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silzle, Tobias, Blum, Sabine, Kasprzak, Annika, Nachtkamp, Kathrin, Rudelius, Martina, Hildebrandt, Barbara, Götze, Katharina S., Gattermann, Norbert, Lauseker, Michael, Germing, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377210/ https://www.ncbi.nlm.nih.gov/pubmed/37509235 http://dx.doi.org/10.3390/cancers15143572

Ejemplares similares

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
por: Silzle, Tobias, et al.
Publicado: (2019)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
por: Kasprzak, Annika, et al.
Publicado: (2021)

P725: BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY
por: Schulz, Felicitas, et al.
Publicado: (2023)

Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts
por: Kasprzak, A., et al.
Publicado: (2022)

Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients
por: Strapatsas, Judith, et al.
Publicado: (2021)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
por: Kasprzak, A., et al.
Publicado: (2020)

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
por: Kuendgen, Andrea, et al.
Publicado: (2018)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview
por: Kuendgen, Andrea, et al.
Publicado: (2021)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes
por: Wu, An, et al.
Publicado: (2021)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
por: Suh, Koung Jin, et al.
Publicado: (2016)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome
por: Ma, Jiale, et al.
Publicado: (2023)

Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma
por: Shin, Su-Jin, et al.
Publicado: (2013)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
por: Gattermann, Norbert
Publicado: (2008)

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
por: Pardanani, A, et al.
Publicado: (2012)

Low Multiplication Value of Absolute Monocyte Count and Absolute Lymphocyte Count at Diagnosis May Predict Poor Prognosis in Neuroblastoma
por: Tamura, Akihiro, et al.
Publicado: (2020)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

Reduction of absolute monocyte counts is associated with the severity of preterm necrotizing enterocolitis
por: Wang, Zhiru, et al.
Publicado: (2023)

Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR
por: Schulz, Felicitas, et al.
Publicado: (2023)

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange
por: Gattermann, Norbert, et al.
Publicado: (2012)

Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era
por: Ho, Ching-Liang, et al.
Publicado: (2015)

High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies
por: Wan, Ziqi, et al.
Publicado: (2021)

Human bocavirus is not detectable in bone marrow from patients with myelodysplastic syndromes
por: Schildgen, Verena, et al.
Publicado: (2011)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2021)

Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
por: Götze, Katharina S., et al.
Publicado: (2018)

Effect of Depth of Electroacupuncture on the IPSS of Patients with Benign Prostatic Hyperplasia
por: Yuan, Hongwei, et al.
Publicado: (2019)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

P1118: PROGNOSTIC SIGNIFICANCE OF ABSOLUTE MONOCYTE COUNT AND LYMPHOCYTE TO MONOCYTE RATIO IN MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA
por: Li, Y., et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
por: Romano, Alessandra, et al.
Publicado: (2022)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dhhkt1fpi5bc49t8ag3vjc0p3d